Surfing the MASH Tsunami
Episodes
S5 - E17.6 - From The Vault: Looking Back At The EASL Congress 2023 Preview & Program Design
02 Jun 2024
Contributed by Lukas
Send a textThis week's Vault looks back to the EASL Congress 2023 and includes Aleksander Krag, Sven Francque and all three surfers: Jörn Schatt...
S5 - E17.5 - Previewing EASL Congress 2024: Focusing On MASLD Drug Development
02 Jun 2024
Contributed by Lukas
Send a textThis final conversation from SurfingMASH's EASL Congress 2024 preview includes two final papers, one covering MASLD drug development, ...
S5 - E17.4 - Previewing EASL Congress 2024: Is Big Data The Future Of MASLD?
02 Jun 2024
Contributed by Lukas
Send a textThis conversation revolves largely around two Big Data presentations Hannes Hagstrom's team is sharing at the EASL Congress. Every oth...
S5 - E17.3 - Previewing EASL Congress 2024: Jörn Schattenberg Joins The MASLD Conversation
01 Jun 2024
Contributed by Lukas
Send a textThis conversation starts with Jörn Schattenberg joining the conversation. The main points are two abstracts, one reviewed by Jörn and the...
S5 - E17.2 - Previewing EASL Congress 2024: Collegiality, Consortia & High-Quality MASLD Abstracts
01 Jun 2024
Contributed by Lukas
Send a textThis conversation starts and ends with thoughts from Michelle Long. Her first comment praises the expanded networking opportunities in the ...
S5 - E17.1 - Previewing EASL Congress 2024: Secretary General Aleksander Krag Shares His Vision For The Congress
01 Jun 2024
Contributed by Lukas
Send a textThis first conversation from our EASL Congress 2024 preview starts with EASL Secretary General Aleksander Krag offering his vision for next...
S5 - E17 - Previewing EASL Congress 2024 and its Major MASLD Moments
30 May 2024
Contributed by Lukas
Send a textNext week, 7,000+ hepatology stakeholders will convene in Milano, Italy, to consume 2,000+ posters and presentations, including an extensiv...
S5 - E16.5 - From The Vault: Stephen Harrison Discusses FASCINATE-2 Results For Denifenstat
26 May 2024
Contributed by Lukas
Send a textIn this excerpt from last July, Stephen Harrison shares results of the FASCINATE-2 study as part of SurfingMASH's larger coverage of e...
S5 - E16.4 - Remembering MASLD Master Stephen Harrison: Stephen As Role Model
26 May 2024
Contributed by Lukas
Send a textThis is the second half of Roger Green's conversation with Dimitar Tonev. It focuses largely on some of the elements of Stephen's...
S5 - E16.3 - Remembering MASLD Master Stephen Harrison: Stephen As Innovator
25 May 2024
Contributed by Lukas
Send a textThe conversation shares the first half of Roger Green's interview with Dimitar Tonev, whose tribute comment to Stephen Roger shared in...
S5 - E16.2 - Remembering MASLD Master Stephen Harrison: Stephen As Patient Advocate
25 May 2024
Contributed by Lukas
Send a textThis conversation includes the second half of Jörn Schattenberg's and Roger Green's interview with Donna Cryer. It focuses large...
S5 - E16.1 - Remembering MASLD Master Stephen Harrison: Stephen As Integrator
25 May 2024
Contributed by Lukas
Send a textThis conversation includes the first half of Jörn Schattenberg's and Roger Green's interview with Donna Cryer. While the questio...
S5 - E16 - Remembering Stephen Harrison 2: More Memories of a MASLD Master
23 May 2024
Contributed by Lukas
Send a textGlobal Liver Institute Founder and CEO Donna Cryer and hepatology researcher and industry executive Dimitar Tonev join Jörn Schattenberg a...
S5-15.6 - From the Vault: Discussing NAIL-NIT Findings at INCBCN 2023
19 May 2024
Contributed by Lukas
Send a textThis week's vault looks back to SurfingMASH's Barcelona coverage in earlier years to identify one point we can use to evaulate pr...
S5 - E15.5 - From SLD Think-Tank 2024 Wrap-Pp: Shall We Focus More on Preventive Hepatology?
19 May 2024
Contributed by Lukas
Send a textThis wrap-up conversation focuses on elements to add and reconsider for #SLDThinkTank 2025. One key concept was to broaden the set of stake...
S5 - E15.4 - From SLD Think-Tank 2024: Improving Preparedness And The Value of Having Rezdiffra
19 May 2024
Contributed by Lukas
Send a textThis conversation from #SLDThinkTank 2024 focuses largely on ways to improve delivery of screening services to patients. Along the way, par...
S5 - E15.3 - From SLD Think-Tank 2024: Meeting Agenda And The "Magic Wand"
18 May 2024
Contributed by Lukas
Send a textAs the Surfers dive deeper into the substance of #SLDThinkTank 2024, Jeff Lazarus describes the meeting agenda and anticipated outputs, and...
S5 - E15.2 - From SLD Think-Tank 2024: An Innovative Stimulating Meeting Design
18 May 2024
Contributed by Lukas
Send a textThe first conversation from our #SLDThinkTank 2024 coverage explores the meeting design from two perspectives. Co-hosts Jeff Lazarus and Jö...
S5 - E15.1 - From SLD Think-Tank 2024: Meet Maja Thiele And Learn About LiverAIM
18 May 2024
Contributed by Lukas
Send a text#SLDThinkTank participant Maja Thiele, a first-time guest, shares her professional history and the traditional "one thing the audience...
S5 - E15 - Highlights from SLD Think-Tank 2024, a Public Health Approach to MASH
16 May 2024
Contributed by Lukas
Send a text#SLDThinkTank 2024 co-chair Jörn Schattenberg and SLD Think Tank co-chair Jeff Lazarus, participants Maja Thiele and Mike Betel and Surfin...
S5 - E14.4 - From the Vault: Our Last Year-End Interview With MASH Master Stephen Harrison
12 May 2024
Contributed by Lukas
Send a textSurfingMASH's last year-end interview with Stephen Harrison took place in 2022. Louise Campbell and Roger Green join Stephen to discus...
S5 E14.2 - Remembering Stephen Harrison: Professional Accomplishments
12 May 2024
Contributed by Lukas
Send a textManal Abdelmalek and Naim Alkhouri join co-hosts Jörn Schattenberg, Louise Campbell and Roger Green to reflect on the greatest professiona...
S5 E14.1 - Remembering Stephen Harrison: Personal Memories
12 May 2024
Contributed by Lukas
Send a textManal Abdelmalek and Naim Alkhouri join co-hosts Jörn Schattenberg, Louise Campbell and Roger Green to share personal memories of co-found...
S5 - E14.3 - Remembering Stephen Harrison: "Harrisonisms"
11 May 2024
Contributed by Lukas
Send a textManal Abdelmalek and Naim Alkhouri join co-hosts Jörn Schattenberg, Louise Campbell and Roger Green to rshare some of their favorite "...
S5 - E14 - Remembering Stephen Harrison - colleagues share memories and impressions of an SLD master
08 May 2024
Contributed by Lukas
Send a textThe sudden passing on April 23 of our co-founder and colleague Stephen Harrison sent shock waves throughout the global SLD community. This ...
S5 - E13.6 - One Year Ago: When Global Fatty Liver Day Was #NASHDay 2023
06 May 2024
Contributed by Lukas
Send a textThis vault conversation looks back to our coverage of International NASHDay 2023, the predecessor title to this year's Global Fatty Li...
S5 - E13.5 - MASH And The Elephant Metaphor: Attacking A Multi-Faceted, Complex Disease
05 May 2024
Contributed by Lukas
Send a textThis closing conversation introduces two new concepts: the idea that MASH has so many facets that it is comparable to the metaphor of blind...
S5 - E13.4 - A Deeper Dive into Care Challenges and Barriers Affecting MASH Patient Care
05 May 2024
Contributed by Lukas
Send a textJeff McIntyre uses the discussion between Louise Campbell and Mike Betel as a jumping-off point for discussing some of the larger care chal...
S5 - E13.3 - Practical Challenges In Patient Care: Role Of GLP-1s And Scanning
04 May 2024
Contributed by Lukas
Send a textThis conversation focuses on what happens after or around patient screening, addressing the challenges caused by using GLP-1s and dual incr...
S5 - E13.2 - Global Fatty Liver Day 2024 And The Rationale Behind "Act Now. Get Screened."
04 May 2024
Contributed by Lukas
Send a textThis conversation centers around the Global Fatty Liver Day 2024 theme and the rationale behind focusing on screening.It starts with Jeff d...
S5 - E13.1 - Remembering SurfingMASH Co-Founder Stephen Harrison
04 May 2024
Contributed by Lukas
Send a textOn April 23, the global MASLD community lost one of its giants when SurfingMASH Co-founder Stephen Harrison passed away unexpectedly. Co-ho...
S5 - E13 - Previewing Global Fatty Liver Day 2024
02 May 2024
Contributed by Lukas
Send a textFatty Liver Alliance Founder and President Mike Betel and Global Liver Institute Vice President for Liver Programs Jeff McIntyre join Louis...
S5 - E12.6 - From The Vault: More Different Roles For NITs In MASH
28 Apr 2024
Contributed by Lukas
Send a textOne theme in this week's episode involves different ways to use NITs in drug development and assessing the value of older drugs in MAS...
S5 - E12.5 - MASH Drug Development: Combining With Old Drugs And Shortening Time To Approval
28 Apr 2024
Contributed by Lukas
Send a textThis wrap-up conversation about MASH Drug Development covers two issues: combination therapies with old drugs and using NITs to speed and s...
S5 - E12.4 - MASH Drug Development: Implications Of Concomitant Metabolic Therapy Use
28 Apr 2024
Contributed by Lukas
Send a textThis conversation starts by focusing on the impact of concomitant metabolic therapies in MASH drug development and patient treatment and th...
S5 - E15.3 - MASH Drug Development: Improvement Since 2020 And Issues That Remain
27 Apr 2024
Contributed by Lukas
Send a textThis conversation includes two sections: one optimizing efficacy endpoints to reflect clinical practice and a second looking back at what h...
S5 - E12.2 - MASH Drug Development: Improving Efficacy Endpoints
27 Apr 2024
Contributed by Lukas
Send a textIn this conversation, the panel discusses challenges in MASH Drug Development that are centered around efficacy endpoints and NAS scoring.T...
S5 - E12.1 - MASH Drug Development: The State Of The Graveyard 2023
27 Apr 2024
Contributed by Lukas
Send a textIn this initial conversation, Sven Francque shares some of the key messages from the MASH Drug Development graveyard paper he co-authored i...
S5 - E12 - MASH Drug Development: What Failures Taught Us About Success
25 Apr 2024
Contributed by Lukas
Send a textIn this conversation, Sven Francque and William Alazawi join Jörn Schattenberg, Louise Campbell, and Roger Green to review papers co-autho...
S5 - E11.6 - From The Vault: Another Strategic Role For Prescribing MASH Drugs
21 Apr 2024
Contributed by Lukas
Send a textEarlier in this episode, the panel discusses different prescribing models for MASH drugs, triggered by Roger Green's question about wh...
S5 - E11.5 - MASH Prescribing Models & The Increasing Challenge Of Keeping Patients In Long-Term Clinical Trials
21 Apr 2024
Contributed by Lukas
Send a textThis final conversation starts by considering prescribing models for other diseases and how they might work here, shifts to discussing the ...
S5 - E11.4 - More Hot MASLD Topics: Inflammation, MD columnists' Advice, FGF-21s
21 Apr 2024
Contributed by Lukas
Send a textThis conversation sees the end of the "hot topics" discussion, followed by Michael Charlton discussing issues and excitement arou...
S5 - E11.3 - Panelists' Hot Topics: Low-Dose Aspirin, SLD Think Tank, Dietary Inflammation Index
20 Apr 2024
Contributed by Lukas
Send a textAfter Michael Charlton finishes discussing research he finds compelling, Jörn Schattenberg and Louise Campbell each describe one item they...
S5 - E11.2 - Defining Therapeutic Futility For Rezdiffra And Discussing Advances In MASLD Translational Medicine
20 Apr 2024
Contributed by Lukas
Send a textMichael Charlton and the Surfers discuss two issues: defining therapeutic futility for Rezdiffra and describing some advances in MASLD tran...
S5 - E11.1 - How The Rezdiffra Approval Has Affected How One Clinic Manages MASH Patients
20 Apr 2024
Contributed by Lukas
Send a textIn this initial conversation, Michael Charlton describes some ways that the presence of Rezdiffra has affected practices and procedures in ...
S5 - E11 - Life With Rezdiffra: Early Impact On MASH Patient Treatment and MASLD Clinical Trials
18 Apr 2024
Contributed by Lukas
Send a textMichael Charlton joins Jörn Schattenberg, Louise Campbell, and Roger Green for a far-reaching conversation that covers ways Rezdiffra is a...
S5 - E10 - Lessons And Insights On Using Basic EHR Data To Screen For Target MASLD Patients
15 Apr 2024
Contributed by Lukas
Send a textThis episode is a follow-up to Season 4, Episode 5, where we met Tim Jobson. His company, Predictive Health Intelligence (PHI), takes a uni...
S5 - E9.6 - From The Vault: An Earlier Look At Screening In The Clinical Care Pathway
07 Apr 2024
Contributed by Lukas
Send a textThis conversation comes from our coverage of The EASL Congress, 2023, when Sven Francque and Ian Rowe joined Jörn Schattenberg and Roger G...
S5 - E9.5 - In-Office Screening Post-Rezdiffra: The Importance Of Predictive Biomarkers
07 Apr 2024
Contributed by Lukas
Send a textThis conversation focuses on how the need for biomarkers will evolve in an era of in-office screening and MASH drugs and ends with answers ...
S5 - E9.4 - In-office MASLD Screening and the Clinical Care Pathway
07 Apr 2024
Contributed by Lukas
Send a textThis conversation explores the implications of increased access to economically viable in-office screening, particularly when primary care ...
S5 - E9.3 - How Will Increased Access To In-Office Scanning Improve MASLD Therapy:
06 Apr 2024
Contributed by Lukas
Send a textThis conversation centers around the different kinds of impact that in-office scanning can have on MASLD therapy, both in terms of improved...
S5 - E9.2 - VCTE Studies Demonstrate That Multiple Nutrition Interventions Can Support MASLD Patients
06 Apr 2024
Contributed by Lukas
Send a textThis conversation explores why different nutrition interventions might help MASLD patients improve their overall liver health and what less...
S5 - E9.1 - VCTE As A Prognostic And Therapeutic Tool For MASLD
06 Apr 2024
Contributed by Lukas
Send a textThis conversation focuses on the role of VCTE in diagnosing, staging and treating MASLD patients, both in terms of prognostic ability of VC...
S5 - E9 - Value of VCTE Or Other In-Office MASLD Monitoring
04 Apr 2024
Contributed by Lukas
Send a textHannes Hagstrom joins Jörn Schattenberg, Louise Campbell and Roger Green to discuss recent research panelists have conducted. This content...
S5 - E8 - Changing Patient Incentives For Participating In MASH Clinical Trials
01 Apr 2024
Contributed by Lukas
Send a textWith Louise Campbell and Jörn Schattenberg both on Easter Week vacations, Fatty Liver Alliance Founder Mike Betel joins Roger Green to con...
S5 - E7.6 - MASLD Patient Advocates' Recommendations for Others after Rezdiffra Approval
24 Mar 2024
Contributed by Lukas
Send a textSo far, this conversation has focused on Rezdiffra approval and its many forms of impact on MASLD patient advocates. This conversation cons...
S5 - E7.5 - Will Increasing the Focus on MASH via Rezdiffra Overwhelm the Healthcare System?
24 Mar 2024
Contributed by Lukas
Send a textThis conversation asks what impact Rezdiffra patient education might have on a U.S. healthcare system in which 38% of American adults live ...
S5 - E7.4 - How MASH patient advocates plan to support Rezdiffra
24 Mar 2024
Contributed by Lukas
Send a textThis conversation focuses on how the role of MASLD patient advocates might change and expand in the aftermath of Rezdiffra being approved. ...
S5 - E7.3 - Patient advocacy and the Rezdiffra label
23 Mar 2024
Contributed by Lukas
Send a textThis conversation focuses on the steps that patient advocates took to educate the FDA on what patients wanted in a MASH drug label, in this...
S5 - E7.1 - Rezdiffra is approved! How patient and their advocates processed the news about the first MASH drug
23 Mar 2024
Contributed by Lukas
Send a textThis conversation focuses on advocates' reactions throughout the day on Thursday, March 14, the day Rezdiffra became the first MASH dr...
S5 - E7.2 - Identifying the target MASH patients for Rezdiffra
23 Mar 2024
Contributed by Lukas
Send a textThis conversation focuses on two issues: (i) identifying the right target MASH patients for Rezdiffra, and (ii) the extensive Madrigal pati...
S5 - E7 - MASLD Patient Advocates Celebrate Rezdiffra and Discuss the Future
21 Mar 2024
Contributed by Lukas
Send a textLast Thursday, March 14, Rezdiffra (resmetirom) became the first drug approved in the US for MASH. Five leading North American MASLD patien...
S5 - E6.6 - Closing Question From The Episode On Rezdiffra, The First MASH Drug
19 Mar 2024
Contributed by Lukas
Send a textAs the conversation wound down, Roger Green offered panelists to address any issue pertaining to Rezdiffra, the first MASH drug, that had n...
S5 - E6.5 - BioPharma Industry Takeaways ForBioPharma Industry Takeaways From The Rezdiffra Launch The Rezdiffra Launch
19 Mar 2024
Contributed by Lukas
Send a textThis conversation revolves around one question: "What lessons should the BioPharma industry take from the launch of Rezdiffra?" A...
S5 - E6.4 - Finding The MASH Patients That Are The Initial Rezdiffra Targets
19 Mar 2024
Contributed by Lukas
Send a textOne pivotal question surrounding the launch of Rezdiffra is "Which MASH patients are the correct targets for the first MASH drug?"...
S5 - E6.3 - Staging and screening patients for Rezdiffra using NITs
18 Mar 2024
Contributed by Lukas
Send a textThis conversation focuses on the necessity of using NITs to screen and identify Rezdiffra patients, while at the same time acknowledging th...
S5 - E6.2 - How Approval Of Rezdiffra,The First MASH Drug, Might Improve Patient Adherence To Lifestyle Recommendations
18 Mar 2024
Contributed by Lukas
Send a textThis conversation focuses on what panelists see as a key (and somewhat unusual) benefit of Rezdiffra: that having a prescription drug for M...
S5 - E6.1 - Rezdiffra Is Approved! How Key Opinion Leaders Processed The News About The First MASH Drug
18 Mar 2024
Contributed by Lukas
Send a textFDA approval of the first MASH drug, Rezdiffra, on March 14 marked what co-host and Key Opinion Leader Jörn Schattenberg describes as a &q...
S5 - E6 - Rezdiffra Is Here! Key Opinion Leaders React To The First MASH Drug Approval
16 Mar 2024
Contributed by Lukas
Send a textLast Thursday, March 14, Rezdiffra (resmetirom) became the first MASH drug approved in the US. A global panel of Key Opinion Leaders conven...
S5 - E5.6 - From The Vault: Tsunami's First Look At MASEF, A Major New NIT
10 Mar 2024
Contributed by Lukas
Send a textThis conversation comes from our first look at MASEF, last September, when lead author Mazen Noureddin joined the Surfers to discuss his re...
S5 - E5.5 - More on GLP-1s and a Broader MASH Wrap-up
10 Mar 2024
Contributed by Lukas
Send a textAfter some final discussion about GLP-1s, this conversation entails Roger Green summarizing what he has heard in the episode so far and tes...
S5 - E5.4 - The dance of drug pricing and patient targets in MASH, PLUS: the role of GLP-1s
10 Mar 2024
Contributed by Lukas
Send a textThis conversation touches on two important subjects: the impact of different potential resmetirom prices on the size and structure of the t...
S5 - E5.3 - Strategies to Improve NIT reliability in Diagnosing and Staging MASH Fibrosis
10 Mar 2024
Contributed by Lukas
Send a textThis conversation focuses more tightly on the specific challenges with the current approaches that use NITs to diagnose and stage advanced ...
S5 - E5.2 - NITs In The Diagnosis and Treatment Of Advanced MASH Fibrosis Patients
10 Mar 2024
Contributed by Lukas
Send a textThis conversation explores the challenges with using the current non-invasive tests (NITs) to diagnose patients with F2/F3 advanced MASH fi...
S5 - E5.1 - Why We Are Focusing On NITs For MASH Diagnosis And Screening
10 Mar 2024
Contributed by Lukas
Send a textThis conversation explores why proper use of non-invasive tests (NITs) will play a pivotal role in increasing the number of patients diagno...
S5 - E5 - How Non-Invasive Tests (NITs) For MASLD And MASH Might Evolve In 2024
07 Mar 2024
Contributed by Lukas
Send a textIn 2024, the two major areas for change in diagnosing and treating MASH are new drug approval and changes in use of NITs. Naim Alkhouri a...
S5 - E4.6 - From The Vault: What a NASH Disease Model Reveals About Treating Advanced Fibrosis
03 Mar 2024
Contributed by Lukas
Send a textTwo years ago, Surfing the MASH Tsunami conducted two episodes with Chris Estes, then the chief modeler for the Center for Disease Analysi...
S5 - E4.5 - MASH Education As A Tool To Stem The MASLD Pandemic
03 Mar 2024
Contributed by Lukas
Send a textAs the episode comes to an end, the group winds up focusing on the need for better, more frequent MASH education as a pivotal need if we ar...
S5 - E 4.4 - Learning about the Global NASH Council's work in MASLD
03 Mar 2024
Contributed by Lukas
Send a textThis conversation focuses largely on the work of the Global NASH Council, an effort of over 200 stakeholders in more than 50 countries to a...
S5 - E4.3 - Slowing The Growth Of The MASLD Pandemic
03 Mar 2024
Contributed by Lukas
Send a textThis conversation starts with a focus on slowing the growth of the MASLD pandemic, and then veers slightly into a discussion of the specifi...
S5 - E4.2 - The Breadth Of MASLD Disease Burden And Cost Effectiveness Of Therapies
03 Mar 2024
Contributed by Lukas
Send a textInitially, this conversation focuses on how cost-effectiveness issues relate to the MASLD Disease Burden. In the process, Zobair Younossi p...
S5 - E4.1 - Appreciating The Disease Burden Of MASLD
03 Mar 2024
Contributed by Lukas
Send a textIn this opening conversation on MASLD disease burden, Zobair Younossi summarizes and expands on some key points from the recent Diabetes Sp...
S5 - E4 - MASLD Epidemiology Takes: Rapidly Proliferating Prevalence; Many Public Health Needs
29 Feb 2024
Contributed by Lukas
Send a textZobair Younossi, Chair of the Global NASL Council, publishes seminal papers on MASLD epidemology, cost of disease, and related public hea...
S5 - E3.6 - From the Vault: EASL Congress 2023: Focus On The New MASLD Nomenclature
27 Feb 2024
Contributed by Lukas
Send a textOur first conversation focusing on the new MASLD nomenclature surfaces as part of our coverage of the EASL Congress 2023. Hepatology resear...
S5 - E3.5 - The New MASLD Nomenclature: What Lies Ahead For MASH Patients And Providers?
27 Feb 2024
Contributed by Lukas
Send a textThis conversation ties up several issues related to MASH and the new MASLD nomenclature that the panel did not touch on earlier in the epis...
S5 - E3.4 - Discussing MASLD With Patients: MASH Is Not "Just A Little Fat" Any More
27 Feb 2024
Contributed by Lukas
Send a textThis conversation focuses on how the new MASLD nomenclature might improve providers' explanations of MASH to patients. Louise Campbell...
S5 - E3.3 - The New MASLD Nomenclature -- MASLD Rollout And Stakeholder Roles
27 Feb 2024
Contributed by Lukas
Send a textThis conversation shifts from the rearview to the path ahead. Louise Campbell starts by asking about the role of Allied Health Providers in...
S5 - E3.2 - How Did The Delphi Process Work For The New MASLD Nomenclature?
27 Feb 2024
Contributed by Lukas
Send a textThis conversation focuses on the Delphi process for a new MASLD nomenclature. It starts with Jeff Lazarus describing what a Delphi process ...
S5 - E3.1 - Why create a new MASLD nomenclature?
26 Feb 2024
Contributed by Lukas
Send a textThis conversation focuses on the issues and visions that led to the identified need for a new MASLD nomenclature. Maru Rinella and Jeff Laz...
S5 - E3 - The New MASLD Nomenclature And How We Got Here
24 Feb 2024
Contributed by Lukas
Send a textThe process of creating a new MASLD nomenclature for the condition formerly known as Fatty Liver Disease was a multi-year process with uniq...
S5 - E2.5 - Conversations From The Vault: Jeff McIntyre On ICER Reviews And NITs
19 Feb 2024
Contributed by Lukas
Send a textThis conversation is part of a March, 2023 interview between co-hosts Louise Campbell and Roger Green and Jeff McIntyre of Global Liver Ins...
S5 - E2.4 - MASLD Patient Advocates' Priority 2024 MASH Programs
18 Feb 2024
Contributed by Lukas
Send a textLeading MASLD patient advocates Jeff McIntyre (Global Liver Institute), Milan Mishkovikj (European Liver Patients Association), Tony Villio...
S5 - E2.3 - Where Do MASLD Patients And Advocates Fit In MASH Drug Access Decisions?
17 Feb 2024
Contributed by Lukas
Send a textLeading MASLD patient advocates Jeff McIntyre (Global Liver Institute), Milan Mishkovikj (European Liver Patients Association), Tony Villio...
S5 - E2.2 - After The First MASH Drug Approval, Focus Shifts To Patient Access
17 Feb 2024
Contributed by Lukas
Send a textLeading patient advocates Jeff McIntyre (Global Liver Institute), Milan Mishkovikj (European Liver Patients Association), Tony Villiotti (N...
S5 - E2.1 - Expectations For The Resmetirom PDUFA Date - The First MASH Drug Approval?
17 Feb 2024
Contributed by Lukas
Send a textLeading patient advocates Jeff McIntyre (Global Liver Institute), Milan Mishkovikj (European Liver Patients Association), Tony Villiotti (N...
S5 - E02 - MASLD Patient Advocates Plan MASH Activities For 2024
15 Feb 2024
Contributed by Lukas
Send a text00:00:00 Surf's Up: Season 5 Episode 2 Co-hosts Louise Campbell and Roger Green sit with four leading MASLD patient advocates (Tony Vi...
S5 - E1.6 - SurfingMASH Is Back! How Can Consumer Behavior Confound MASH Care?
11 Feb 2024
Contributed by Lukas
Send a textAfter a month off in January, SurfingMASH returns for the 2024 calendar year. In this last segment of Episode 1, the co-hosts explore the c...
S5 -E1.5 - SurfingMASH Is Back! How Will GLP-1 Ads From Telemedicine Affect MASH?
11 Feb 2024
Contributed by Lukas
Send a textAfter a month off in January, SurfingMASH returns for the 2024 calendar year. In this conversation, the group examines the explosion of tel...
S5 - E1.4 - SurfingMASH Is Back! Reframing "Liver Awareness" In The Context Of US DTC Advertising
11 Feb 2024
Contributed by Lukas
Send a textAfter a month off in January, SurfingMASH returns for the 2024 calendar year. In this conversation, the group explores the goal of provider...
S5 - E1.3 - SurfingMASH Is Back! 2024 Podcast Updates And The Increasing Need For "Liver Awareness"
10 Feb 2024
Contributed by Lukas
Send a textAfter a month off in January, SurfingMASH returns for the 2024 calendar year. In this conversation, Louise Campbell describes how VCTE can ...